Impact of HIV type 1 subtype on drug resistance mutations in Nigerian patients failing first-line therapy

AIDS Research and Human Retroviruses

Volumn 27, Issue 1, 2011, Pages 71-80

  Chaplin, B ^a   Eisen, G ^a   Idoko, J ^b   Onwujekwe, D ^c   Idigbe, E ^c   Adewole, I ^d   Gashau, W ^e   Meloni, S ^a   Sarr, A D ^a   Sankale J L ^a   Ekong, E ^a   Murphy, R L ^f   Kanki, P ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF JOS   (Nigeria)

^c NIGERIAN INSTITUTE OF MEDICAL RESEARCH   (Nigeria)

^d UNIVERSITY OF IBADAN   (Nigeria)

^e Maiduguri Teaching Hospital   (Nigeria)

^f NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; LAMIVUDINE; STAVUDINE; TENOFOVIR; THYMIDINE DERIVATIVE; ZIDOVUDINE;

ARTICLE; CONTROLLED STUDY; DRUG TREATMENT FAILURE; GENE SEQUENCE; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; NIGERIA; NONHUMAN; PHYLOGENETIC TREE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STRUCTURAL GENE; VIRUS GENE; VIRUS MUTATION;

AMINO ACID SUBSTITUTION; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HIV INFECTIONS; HIV PROTEASE; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; MALE; MOLECULAR SEQUENCE DATA; MUTATION, MISSENSE; NIGERIA; RNA, VIRAL; SEQUENCE ANALYSIS, DNA; TREATMENT FAILURE;

EID: 78651462061     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2010.0050     Document Type: Article

References (54)

1. Hemelaar J, Gouws E, Ghys PD, and Osmanov S: Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004. AIDS 2006;20:W13-23.
2. Essex M: HIV Variability in Africa. 2009; A Line Drawn in the Sand: Responses to the AIDS Treatment Crisis in Africa: 247-261.
3. Hamel DJ, Sankale JL, Eisen G, et al.: Twenty years of prospective molecular epidemiology in Senegal: Changes in HIV diversity. AIDS Res Hum Retroviruses 2007;23:1189-1196.
4. Howard TM, Olaleye DO, and Rasheed S: Sequence analysis of the glycoprotein 120 coding region of a new HIV type 1 strain (HIV-1 IbNg) from Nigeria. AIDS Res Human Retroviruses 1994;10:1755-1757.
5. Sankale JL, Langevin S, Odaibo G, et al.: The complexity of circulating HIV type 1 strains in Oyo state, Nigeria. AIDS Res Hum Retroviruses 2007;23:1020-1025.
6. Brennan CA, Bodelle P, Coffey R, et al.: The prevalence of diverse HIV-1 strains was stable in Cameroonian blood donors from 1996 to 2004. J Acquir Immune Defic Syndr 2008;49:432-439.
7. Ellenberger DL, Pieniazek D, Nkengasong J, et al.: Genetic analysis of human immunodeficiency virus in Abidjan, Ivory Coast reveals predominance of HIV type 1 subtype A and introduction of subtype G. AIDS Res Hum Retroviruses 1999;15:3-9.
8. Cham F, Heyndrickx L, Janssens W, et al.: Study of HIV type 1 gag/env variability in The Gambia, using a multiplex DNA polymerase chain reaction. AIDS Res Hum Retroviruses 2000;16:1915-1919.
9. Ode H, Matsuyama S, Hata M, Hoshino T, Kakizawa J, and Sugiura W: Mechanism of drug resistance due to N88S in CRF01-AE HIV-1 protease, analyzed by molecular dynamics simulations. J Med Chem 2007;50:1768-1777.
10. Dumans AT, Barreto CC, Santos AF, et al.: Distinct resistance mutation and polymorphism acquisition in HIV-1 protease of subtypes B and F1 from children and adult patients under virological failure. Infect Genet Evol 2009;9:62-70.
11. Hosseinipour MC, van Oosterhout JJ, Weigel R, et al.: The public health approach to identify antiretroviral therapy failure: High-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. AIDS 2009;23:1127-1134.
12. Doualla-Bell F, Gaolathe T, Avalos A, et al.: Five-year follow up of genotypic resistance patterns in HIV-1 subtype C infected patients in Botswana after failure of thymidine analogue- based regimens. J Int AIDS Soc 2009;12:25.
13. Brenner BG, Oliveira M, Doualla-Bell F, et al.: HIV-1 subtypeC viruses rapidly develop K65R resistance to tenofovir in cell culture. AIDS 2006;20:F9-13.
14. Xu HT, Martinez-Cajas JL, Ntemgwa ML, et al.: Effects of the K65R and K65R/M184V reverse transcriptase mutations in subtype C HIV on enzyme function and drug resistance. Retrovirology 2009;6:14.
15. Sagoe KW, Dwidar M, Lartey M, et al.: Variability of the human immunodeficiency virus type 1 polymerase gene from treatment naive patients in Accra, Ghana. J Clin Virol 2007;40:163-167.
16. Holguin A, Paxinos E, Hertogs K, Womac C, and Soriano V: Impact of frequent natural polymorphisms at the protease gene on the in vitro susceptibility to protease inhibitors in HIV-1 non-B subtypes. J Clin Virol 2004;31:215-220.
17. Liu J, Yue J, Wu S, and Yan Y: Polymorphisms and drug resistance analysis of HIV-1 CRF01-AE strains circulating in Fujian Province, China. Arch Virol 2007;152:1799-1805.
18. Vergne L, Stuyver L, Van Houtte M, Butel C, Delaporte E, and Peeters M: Natural polymorphism in protease and reverse transcriptase genes and in vitro antiretroviral drug susceptibilities of non-B HIV-1 strains from treatment-na've patients. J Clin Virol 2006;36:43-49.
19. Kinomoto M, Appiah-Opong R, Brandful JA, et al.: HIV-1 proteases from drug-naive West African patients are differentially less susceptible to protease inhibitors. Clin Infect Dis 2005;41:243-251.
20. Coman RM, Robbins AH, Fernandez MA, et al.: The contribution of naturally occurring polymorphisms in altering the biochemical and structural characteristics of HIV-1 subtype C protease. Biochemistry 2008;47:731-743.
21. Sanches M, Krauchenco S, Martins NH, Gustchina A, Wlodawer A, and Polikarpov I: Structural characterization of B and non-B subtypes of HIV-protease: Insights into the natural susceptibility to drug resistance development. J Mol Biol 2007;369:1029-1040.
22. Bessong PO: Polymorphisms in HIV-1 subtype C proteases and the potential impact on protease inhibitors. Trop Med Int Health 2008;13:144-151.
23. Champenois K, Deuffic-Burban S, Cotte L, et al.: Natural polymorphisms in HIV-1 protease: Impact on effectiveness of a first-line lopinavir-containing antiretroviral therapy regimen. J Med Virol 2008;80:1871-1879.
24. Lawrence P, Lutz MF, Saoudin H, et al.: Analysis of polymorphism in the protease and reverse transcriptase genes of HIV type 1 CRF02-AG subtypes from drug-naive patients from Saint-Etienne, France. J Acquir Immune Defic Syndr 2006;42:396-404.
25. Federal Ministry of Health N: HIV/Syphilis Sero-Prevalence and STD Syndromes Sentinel Survey among PTB and STD Patients in Nigeria. Federal Ministry of Health, Abuja, 2007
26. The United States President's Emergency Plan for AIDS Relief [http://www.pepfar.gov/].
27. Kanki PJ: The Challenge and Response in Nigeria. Harvard Series on Population and Development Studies 2009; A Line Drawn in the Sand: Responses to the AIDS Treatment Crisis in Africa.
28. Idigbe EO, Adewole TA, Eisen G, et al.: Management of HIV- 1 infection with a combination of nevirapine, stavudine, and lamivudine: A preliminary report on the Nigerian antiretroviral program. J Acquir Immune Defic Syndr 2005;40:65-69.
29. Boileau C, Nguyen VK, Sylla M, et al.: Low prevalence of detectable HIV plasma viremia in patients treated with antiretroviral therapy in Burkina Faso and Mali. J Acquir Immune Defic Syndr 2008;48:476-484.
30. Sow PS, Otieno LF, Bissagnene E, et al.: Implementation of an antiretroviral access program for HIV-1-infected individuals in resource-limited settings: Clinical results from 4 African countries. J Acquir Immune Defic Syndr 2007;44: 262-267.
31. Johnson VA, Brun-Vezinet F, Clotet B, et al.: Update of the drug resistance mutations in HIV-1: Spring 2008. Top HIV Med 2008;16:62-68.
32. Larkin MA, Blackshields G, Brown NP, et al.: Clustal W and Clustal X version 2.0. Bioinformatics 2007;23:2947-2948.
33. Hosmer DWJ, Wang CY, Lin IC, and Lemeshow S: A computer program for stepwise logistic regression using maximum likelihood estimation. Comput Programs Biomed 1978;8:121-134.
34. Meloni S, Ekong E, Onwujekwe D, et al.: Rate of Viral Load Suppression Higher in Women than Men in Large ART Program in Nigeria. 16th Conference on Retroviruses and Opportunistic Infections, 2009.
35. Meloni ST, Sankale JL, Hamel DJ, et al.: Molecular epidemiology of human immunodeficiency virus type 1 subsubtype A3 in Senegal from 1988 to 2001. J Virol 2004;78: 12455-12461.
36. Peeters M, Esu-Williams E, Vergne L, et al.: Predominance of subtype A and G HIV type 1 in Nigeria, with geographical differences in their distribution. AIDS Res Hum Retroviruses 2000;16:315-325.
37. Meloni ST, Sankalé JL, Odaibo G, Olaleye DO, and Kanki PJ: A Nigeria-specific cluster of HIV-1 subtype G is sustained in full-length genomes sequencing. 14th International Conference on AIDs and STIs in Africa, 2005.
38. Kisic M, Mendieta J, Puertas MC, et al.: Mechanistic basis of zidovudine hypersusceptibility and lamivudine resistance conferred by the deletion of codon 69 in the HIV-1 reverse transcriptase coding region. J Mol Biol 2008;382:327-341.
39. Villena C, Prado JG, Puertas MC, et al.: Relative fitness and replication capacity of a multinucleoside analogue-resistant clinical human immunodeficiency virus type 1 isolate with a deletion of codon 69 in the reverse transcriptase coding region. J Virol 2007;81:4713-4721.
40. Menendez-Arias L, Matamoros T, and Cases-Gonzalez CE: Insertions and deletions in HIV-1 reverse transcriptase: Consequences for drug resistance and viral fitness. Curr Pharm Des 2006;12:1811-1825.
41. Liu TF and Shafer RW: Web resources for HIV type 1 genotypic-resistance test interpretation. Clin Infect Dis 2006; 42:1608-1618.
42. Sankale JL, Hamel D, Woolsey A, et al.: Molecular evolution of human immunodeficiency virus type 1 subtype A in Senegal: 1988-1997. J Hum Virol 2000;3:157-164.
43. Hawkins CA, Chaplin B, Idoko J, et al.: Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. J Acquir Immune Defic Syndr 2009;52(2):228-234.
44. van de Vijver DA, Wensing AM, Angarano G, et al.: The calculated genetic barrier for antiretroviral drug resistance substitutions is largely similar for different HIV-1 subtypes. J Acquir Immune Defic Syndr 2006;41:352-360.
45. Marcelin AG, Delaugerre C, Wirden M, et al.: Thymidine analogue reverse transcriptase inhibitors resistance mutations profiles and association to other nucleoside reverse transcriptase inhibitors resistance mutations observed in the context of virological failure. J Med Virol 2004;72:162-165.
46. Puertas MC, Buzon MJ, Artese A, et al.: Effect of the human immunodeficiency virus type 1 reverse transcriptase polymorphism Leu-214 on replication capacity and drug susceptibility. J Virol 2009;83:7434-7439.
47. Sturmer M, Staszewski S, Doerr HW, Larder B, Bloor S, and Hertogs K: Correlation of phenotypic zidovudine resistance with mutational patterns in the reverse transcriptase of human immunodeficiency virus type 1: Interpretation of established mutations and characterization of new polymorphisms at codons 208, 211, and 214. Antimicrob Agents Chemother 2003;47:54-61.
48. Novitsky V, Wester CW, DeGruttola V, et al.: The reverse transcriptase 67N 70R 215Y genotype is the predominant TAM pathway associated with virologic failure among HIV type 1C-infected adults treated with ZDV/ddI-containing HAART in southern Africa. AIDS Res Hum Retroviruses 2007;23:868-878.
49. Martinez-Cajas JL, Pai NP, Klein MB, and Wainberg MA: Differences in resistance mutations among HIV-1 nonsubtype B infections: A systematic review of evidence (1996- 2008). J Int AIDS Soc 2009;12:11.
50. Kantor R, Katzenstein DA, Efron B, et al.: Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. PLoS Med 2005;2:e112.
51. Palma AC, Abecasis AB, Vercauteren J, et al.: Effect of human immunodeficiency virus type 1 protease inhibitor therapy and subtype on development of resistance in subtypes B and G. Infect Genet Evol 2010;10(3):373-379.
52. Soares EA, Santos AF, Sousa TM, et al.: Differential drug resistance acquisition in HIV-1 of subtypes B and C. PLoS ONE 2007;2:e730.
53. Taiwo B, Chaplin B, Stanton J, et al.: Etravirine-resistance Mutations in Patients with Virologic Failure on Nevirapine or Efavirenz-based HAART. 15th Conference on Retroviruses and Opportunistic Infections, 2008; Abstract 867.
54. Ojesina AI, Sankale JL, Odaibo G, et al.: Subtype-specific patterns in HIV Type 1 reverse transcriptase and protease in Oyo State, Nigeria: Implications for drug resistance and host response. AIDS Res Hum Retroviruses 2006;22:770-779.